Emerging pharmacotherapies for alcohol dependence: A systematic review focusing on reduction in consumption

Drug and Alcohol Dependence

Volumn 133, Issue 1, 2013, Pages 15-29

  Aubin, Henri Jean ^a   Daeppen, Jean Bernard ^b  

^a Universite Paris Sud   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Abstinence; Alcohol dependence; Burden; Reduction in consumption; Systematic review; Treatment

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACAMPROSATE; ALCOHOL; ARIPIPRAZOLE; BACLOFEN; CARBAMAZEPINE; DISULFIRAM; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR BLOCKING AGENT; ESCITALOPRAM; FLUMAZENIL; FLUPENTIXOL; FLUVOXAMINE; GABAPENTIN; GALANTAMINE; LISURIDE; NALMEFENE; NALTREXONE; OLANZAPINE; ONDANSETRON; OXCARBAZEPINE; PLACEBO; SERTRALINE; TIAGABINE; TIAPRIDE; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZONISAMIDE;

ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; COMORBIDITY; DETOXIFICATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; HUMAN; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RELAPSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE;

ABSTINENCE; ALCOHOL DEPENDENCE; BURDEN; REDUCTION IN CONSUMPTION; SYSTEMATIC REVIEW; TREATMENT;

ALCOHOL ABSTINENCE; ALCOHOL DETERRENTS; ALCOHOL DRINKING; ALCOHOLISM; FLUPENTHIXOL; FLUVOXAMINE; FRUCTOSE; HUMANS; NALTREXONE; PIPERAZINES; PSYCHOTROPIC DRUGS; QUINOLONES;

EID: 84884412326     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.04.025     Document Type: Review

References (88)

1. Addolorato G., Caputo F., Capristo E., Domenicali M., Bernardi M., Janiri L., Agabio R., Colombo G., Gessa G.L., Gasbarrini G. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol. 2002, 37:504-508.
2. Addolorato G., Ancona C., Capristo E., Gasbarrini G. Metadoxine in the treatment of acute and chronic alcoholism: a review. Int. J. Immunopathol. Pharmacol. 2003, 16:207-214.
3. Addolorato G., Leggio L., Ferrulli A., Cardone S., Vonghia L., Mirijello A., Abenavoli L., D'Angelo C., Caputo F., Zambon A., Haber P.S., Gasbarrini G. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007, 370:1915-1922.
4. Addolorato G., Leggio L., Ferrulli A., Cardone S., Bedogni G., Caputo F., Gasbarrini G., Landolfi R. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol Alcohol. 2011, 46:312-317.
5. Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., Bryson H., de Girolamo G., Graaf R., Demyttenaere K., Gasquet I., Haro J.M., Katz S.J., Kessler R.C., Kovess V., Lepine J.P., Ormel J., Polidori G., Russo L.J., Vilagut G., Almansa J., Arbabzadeh-Bouchez S., Autonell J., Bernal M., Buist-Bouwman M.A., Codony M., Domingo-Salvany A., Ferrer M., Joo S.S., Martinez-Alonso M., Matschinger H., Mazzi F., Morgan Z., Morosini P., Palacin C., Romera B., Taub N., Vollebergh W.A. Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiat. Scand. 2004, 420:47-54.
6. Ambrogne J.A. Reduced-risk drinking as a treatment goal: what clinicians need to know. J. Subst. Abuse Treat. 2002, 22:45-53.
7. Ameisen O. Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician. Alcohol Alcohol. 2005, 40:147-150.
8. American Psychiatric Association, 1987. Diagnostic and Statistical Manual of Mental Disorders, Third Edition-Text Revision American Psychiatric Association, Washington, DC.
9. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington D.C. Fourth Edition.
10. American Psychiatric Association, 2000. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-Text Revision American Psychiatric Association, Washington D.C.
11. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., Gastfriend D.R., Hosking J.D., Johnson B.A., LoCastro J.S., Longabaugh R., Mason B.J., Mattson M.E., Miller W.R., Pettinati H.M., Randall C.L., Swift R., Weiss R.D., Williams L.D., Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006, 295:2003-2017.
12. Anton R.F., Kranzler H., Breder C., Marcus R.N., Carson W.H., Han J. A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J. Clin. Psychopharmacol. 2008, 28:5-12.
13. Anton R.F., Myrick H., Baros A.M., Latham P.K., Randall P.K., Wright T.M., Stewart S.H., Waid R., Malcolm R. Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J. Clin. Psychopharmacol. 2009, 29:334-342.
14. Anton R.F., Myrick H., Wright T.M., Latham P.K., Baros A.M., Waid L.R., Randall P.K. Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am. J. Psychiatry 2011, 168:709-717.
15. Arias A.J., Armeli S., Gelernter J., Covault J., Kallio A., Karhuvaara S., Koivisto T., Makela R., Kranzler H.R. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol. Clin. Exp. Res. 2008, 32:1159-1166.
16. Arias A.J., Feinn R., Oncken C., Covault J., Kranzler H.R. Placebo-controlled trial of zonisamide for the treatment of alcohol dependence. J. Clin. Psychopharmacol. 2010, 30:318-322.
17. Baltieri D.A., Daro F.R., Ribeiro P.L., de Andrade A.G. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008, 103:2035-2044.
18. Bender S., Scherbaum N., Soyka M., Ruther E., Mann K., Gastpar M. The efficacy of the dopamine D2/D3 antagonist tiapride in maintaining abstinence: a randomized, double-blind, placebo-controlled trial in 299 alcohol-dependent patients. Int. J. Neuropsychopharmacol. 2007, 10:653-660.
19. Chick J., Aschauer H., Hornik K. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend. 2004, 74:61-70.
20. Collins G.B., McAllister M.S., Adury K. Drug adjuncts for treating alcohol dependence. Cleveland Clinic J. Med. 2006, 73:641-644. 647-648, 650-651, passim.
21. Croissant B., Diehl A., Klein O., Zambrano S., Nakovics H., Heinz A., Mann K. A pilot study of oxcarbazepine versus acamprosate in alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2006, 30:630-635.
22. De Sousa A.A., De Sousa J., Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J. Subst. Abuse Treat. 2008, 34:460-463.
23. Department of Health, 2004. Alcohol Needs Assessment Research Project (ANARP) (cited 2012 20 April); Available from:. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4122239.pdf.
24. DiClemente C.C., Bellino L.E., Neavins T.M. Motivation for change and alcoholism treatment. Alcohol Res. Health 1999, 23:86-92.
25. Dundon W., Lynch K.G., Pettinati H.M., Lipkin C. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol. Clin. Exp. Res. 2004, 28:1065-1073.
26. EMA, 2010. Guideline on the development of medicinal products for the treatment of alcohol dependence (cited 2012 June 18); Available from:. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/03/WC500074898.pdf.
27. EMA, 2013. European public assessment report (EPAR) for Selincro (cited 2013 March 15); Available from:. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002583/human_med_001620.jsp%26mid=WC0b01ac058001d124.
28. Farren C.K., Scimeca M., Wu R., Malley S.O. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug Alcohol Depend. 2009, 99:317-321.
29. Fernandez Miranda J., Marina Gonzalez P., Montes Perez M., Diaz Gonzalez T., Gutierrez Cienfuegos E., Antuna Diaz M., Bobes Garcia J. Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow-up study. Actas Esp. Psiquiatr. 2007, 35:236-242.
30. Feuerlein W., Ringer C., Kuefner H., Antons K. Diagnosis of alcoholism: the Munich Alcoholism Test (MALT). Currents of Alcoholism 1980, Grune & Stratton, New York. M. Galanter (Ed.).
31. Florez G., Garcia-Portilla P., Alvarez S., Saiz P.A., Nogueiras L., Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol. Clin. Exp. Res. 2008, 32:1251-1259.
32. Florez G., Saiz P.A., Garcia-Portilla P., Alvarez S., Nogueiras L., Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur. Addict. Res. 2011, 17:29-36.
33. Furieri F.A., Nakamura-Palacios E.M. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry 2007, 68:1691-1700.
34. Garbutt J.C., West S.L., Carey T.S., Lohr K.N., Crews F.T. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999, 281:1318-1325.
35. Garbutt J.C., Kampov-Polevoy A.B., Gallop R., Kalka-Juhl L., Flannery B.A. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcohol. Clin. Exp. Res. 2010, 34:1849-1857.
36. Gastfriend D.R., Garbutt J.C., Pettinati H.M., Forman R.F. Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst. Abuse Treat. 2007, 33:71-80.
37. Gual, A., He, Y., Torup, L., van den Brink, W., Mann, K., 2012. ESENSE 2: a randomised, double-blind, placebo-controlled study of nalmefene, as-needed use in alcohol dependent patients. Presented at the 35th Annual Scientific Meeting of the Research Society on Alcoholism, June 23-27, San Francisco, California. Alcohol. Clin. Exp. Res. 36, 246A.
38. Guardia J., Segura L., Gonzalvo B., Iglesias L., Roncero C., Cardus M., Casas M. A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol. Clin. Exp. Res. 2004, 28:736-745.
39. Guerrini I., Gentili C., Nelli G., Guazzelli M. A follow up study on the efficacy of metadoxine in the treatment of alcohol dependence. Subst. Abuse Treat. Prev. Policy 2006, 1:35.
40. Hodgins D.C., Leigh G., Milne R., Gerrish R. Drinking goal selection in behavioral self-management treatment of chronic alcoholics. Addict. Behav. 1997, 22:247-255.
41. Johnson B.A., Roache J.D., Javors M.A., DiClemente C.C., Cloninger C.R., Prihoda T.J., Bordnick P.S., Ait-Daoud N., Hensler J. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: a randomized controlled trial. JAMA 2000, 284:963-971.
42. Johnson B.A., Ait-Daoud N., Bowden C.L., DiClemente C.C., Roache J.D., Lawson K., Javors M.A., Ma J.Z. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003, 361:1677-1685.
43. Johnson B.A., Ait-Daoud N., Akhtar F.Z., Ma J.Z. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch. Gen. Psychiatry 2004, 61:905-912.
44. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O'Malley S.S., Swift R.M. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007, 298:1641-1651.
45. Johnson B.A., Rosenthal N., Capece J.A., Wiegand F., Mao L., Beyers K., McKay A., Ait-Daoud N., Addolorato G., Anton R.F., Ciraulo D.A., Kranzler H.R., Mann K., O'Malley S.S., Swift R.M. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch. Intern. Med. 2008, 168:1188-1199.
46. Johnson B.A., Ait-Daoud N., Seneviratne C., Roache J.D., Javors M.A., Wang X.Q., Liu L., Penberthy J.K., DiClemente C.C., Li M.D. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am. J. Psychiatry 2011, 168:265-275.
47. Karhuvaara S., Simojoki K., Virta A., Rosberg M., Loyttyniemi E., Nurminen T., Kallio A., Makela R. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcohol. Clin. Exp. Res. 2007, 31:1179-1187.
48. Kohn R., Saxena S., Levav I., Saraceno B. The treatment gap in mental health care. Bull. World Health Organ. 2004, 82:858-866.
49. Kranzler H.R., Pierucci-Lagha A., Feinn R., Hernandez-Avila C. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol. Clin. Exp. Res. 2003, 27:1150-1155.
50. Kranzler H.R., Armeli S., Tennen H., Covault J., Feinn R., Arias A.J., Pettinati H., Oncken C. A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype. J. Clin. Psychopharmacol. 2011, 31:22-30.
51. Ma J.Z., Ait-Daoud N., Johnson B.A. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction 2006, 101:1561-1568.
52. Mann K., Ackermann K., Diehl A., Ebert D., Mundle G., Nakovics H., Reker T., Richter G., Schmidt L.G., Driessen M., Rettig K., Opitz K., Croissant B. Galantamine: a cholinergic patch in the treatment of alcoholism: a randomized, placebo-controlled trial. Psychopharmacol. (Berl.) 2006, 184:115-121.
53. Mann K., Bladstrom A., Torup L., Gual A., van den Brink W. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene. Biol. Psych. 2012, 73:706-713.
54. Marlatt G.A., Witkiewitz K. Harm reduction approaches to alcohol use: health promotion, prevention, and treatment. Addict. Behav. 2002, 27:867-886.
55. Marra D., Warot D., Berlin I., Hispard E., Notides C., Tilikete S., Payan C., Lepine J.P., Dally S., Aubin H.J. Amisulpride does not prevent relapse in primary alcohol dependence: results of a pilot randomized, placebo-controlled trial. Alcohol. Clin. Exp. Res. 2002, 26:1545-1552.
56. McGlynn E.A., Asch S.M., Adams J., Keesey J., Hicks J., DeCristofaro A., Kerr E.A. The quality of health care delivered to adults in the United States. N. Engl. J. Med. 2003, 348:2635-2645.
57. Moos R.H., Moos B.S. Rates and predictors of relapse after natural and treated remission from alcohol use disorders. Addiction 2006, 101:212-222.
58. Narayana P.L., Gupta A.K., Sharma P.K. Use of anti-craving agents in soldiers with alcohol dependence syndrome. MJAFI 2008, 64:320-324.
59. National Institute on Alcohol Abuse and Alcoholism, 2006. Cognitive Behavioral Coping Skills Therapy Manual [cited 2013 13 March].
60. O'Malley S.S., Robin R.W., Levenson A.L., GreyWolf I., Chance L.E., Hodgkinson C.A., Romano D., Robinson J., Meandzija B., Stillner V., Wu R., Goldman D. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol. Clin. Exp. Res. 2008, 32:1271-1283.
61. Paparrigopoulos T., Tzavellas E., Karaiskos D., Malitas P., Liappas I. An open pilot study of tiagabine in alcohol dependence: tolerability and clinical effects. J. Psychopharmacol. 2010, 24:1375-1380.
62. Parhar K.K., Wormith J.S., Derkzen D.M., Beauregard A.M. Offender coercion in treatment: a meta-analysis of effectiveness. Crim. Justice Behav. 2008, 35:1109-1135.
63. Pettinati H.M., Volpicelli J.R., Luck G., Kranzler H.R., Rukstalis M.R., Cnaan A. Double-blind clinical trial of sertraline treatment for alcohol dependence. J. Clin. Psychopharmacol. 2001, 21:143-153.
64. Pettinati H.M., Dundon W., Lipkin C. Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence. Am. J. Addict. 2004, 13:236-247.
65. Rehm J., Mathers C., Popova S., Thavorncharoensap M., Teerawattananon Y., Patra J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009, 373:2223-2233.
66. Roache J.D., Wang Y., Ait-Daoud N., Johnson B.A. Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism. Alcohol. Clin. Exp. Res. 2008, 32:1502-1512.
67. Rolland B., Bordet R., Cottencin O. Alcohol-dependence: the current French craze for baclofen. Addiction 2012, 107:848-849.
68. Rosner S., Leucht S., Lehert P., Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J. Psychopharmacol. 2008, 22:11-23.
69. Rosner S., Hackl-Herrwerth A., Leucht S., Vecchi S., Srisurapanont M., Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev. 2010, CD001867.
70. Rubio G., Martinez-Gras I., Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J. Clin. Psychopharmacol. 2009, 29:584-589.
71. Rubio G., Lopez-Munoz F., Ferre F., Martinez-Gras I., Ponce G., Pascual J.M., Jimenez-Arriero M.A., Alamo C. Effects of zonisamide in the treatment of alcohol dependence. Clin. Neuropharmacol. 2010, 33:250-253.
72. Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. Addiction 1993, 88:791-804.
73. SAMHSA, 2009. The NSDUH Report: Alcohol Treatment: Need, Utilization, and Barriers. Rockville, MD.
74. Schmidt L.G., Kuhn S., Smolka M., Schmidt K., Rommelspacher H. Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:209-217.
75. Selzer M.L. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am. J. Psychiatry 1971, 127:1653-1658.
76. Sobell L.C., Sobell M.B. Timeline followback: A technique for assessing self-reported alcohol consumption. Measuring Alcohol Consumption: Psychosocial and Biological Methods 1992, 41-72. Humana Press, New Jersey. R.Z.L.J. Allen (Ed.).
77. Stella L., Addolorato G., Rinaldi B., Capuano A., Berrino L., Rossi F., Maione S. An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients. Pharmacol. Res. 2008, 57:312-317.
78. van den Brink, W., Aubin, H.-J., Bladstrom, A., Torup, L., Mann, K., Gual, A., 2013a. ESENSE 1-Randomised controlled 6-month study of as-needed nalmefene: subgroup analysis of alcohol dependent patients with high drinking risk level. Presented at the 21st European Congress of Psychiatry, April 6-9, Nice, France.
79. van den Brink, W, Aubin, H.-J., Sorensen, P., Torup, L., Mann, K., Gual, A., 2013b. ESENSE 2-Randomised controlled 6-month study of as-needed nalmefene: subgroup analysis of alcohol dependent patients with high drinking risk level. Presented at the 21st European Congress of Psychiatry, April 6-9, Nice, France.
80. van den Brink, W., Sorensen, P., Mann, K., Gual, A., 2013c. Long-term efficacy of nalmefene as-needed in alcohol-dependent patients with high drinking risk levels: results of a subgroup analysis. Presented at the 21st European Congress of Psychiatry, April 6-9, Nice, France.
81. van den Brink, W., Sorensen, P., Torup, L., Gual, A., 2012. Long-term efficacy, tolerability, and safety of nalmefene as-needed in alcohol-dependence: a randomised, double-blind, placebo-controlled study. Presented at the 35th Annual Scientific Meeting of the Research Society on Alcoholism, June 23-27, San Francisco, California. Alcohol. Clin. Exp. Res. 36, 247A.
82. Volpicelli J.R., Alterman A.I., Hayashida M., O'Brien C.P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry 1992, 49:876-880.
83. Volpicelli J.R., Pettinati H.M., McLellan A.T., O'Brien C.H.P. Enhanced Medication and Treatment Adherence for Addiction Treatment 2001, The BRENDA Model Guilford Press, New York.
84. Wiesbeck G.A., Weijers H.G., Lesch O.M., Glaser T., Toennes P.J., Boening J. Flupenthixol decanoate and relapse prevention in alcoholics: results from a placebo-controlled study. Alcohol Alcohol. 2001, 36:329-334.
85. Wiesbeck G.A., Weijers H.G., Wodarz N., Lesch O.M., Glaser T., Boening J. Gender-related differences in pharmacological relapse prevention with flupenthixol decanoate in detoxified alcoholics. Arch. Womens Ment. Health 2003, 6:259-262.
86. World Health Organization, 1992. International Statistical Classification of Diseases and Related Health Problems. Geneva, Switzerland.
87. World Health Organization, 2004. The Global Burden of Disease. 2004 update (cited 2012 July 26); Available from:. http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf.
88. World Health Organization, 2007. WHO Expert Committee on Problems Related to Alcohol Consumption (cited 2012 30 July); Available from:. http://www.who.int/substance_abuse/expert_committee_alcohol_trs944.pdf.